Chen Yongli, Yang Yikun, Feng Jinglong, Carrier Andrew J, Tyagi Deependra, Yu Xin, Wang Chunguang, Oakes Ken D, Zhang Xu
Department of Biological Applied Engineering, Shenzhen Key Laboratory of Fermentation Purification and Analysis, Shenzhen Polytechnic, Shenzhen, 518055, China.
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, China.
Acta Biomater. 2022 Oct 15;152:210-220. doi: 10.1016/j.actbio.2022.09.001. Epub 2022 Sep 8.
Simultaneous isolation of various circulating tumor cell (CTC) subtypes from whole blood is useful in cancer diagnosis and prognosis. Microfluidic affinity separation devices are promising for CTC separation because of their high throughput capacity and automatability. However, current affinity agents, such as antibodies (mAbs) and aptamers (Apts) alone, are still suboptimal for efficient, consistent, and versatile cell analysis. By introducing a hybrid affinity agent, i.e., an aptamer-antibody (Apt-mAb) conjugate, we developed a universal and regenerative microchip with high efficiency and non-invasiveness in the separation and profiling of various CTCs from blood. The Apt-mAb conjugate consists of a monoclonal antibody that specifically binds the target cell receptor and a surface-bound aptamer that recognizes the conserved Fc region of the mAb. The aptamer then indirectly links the surface functionalization of the microfluidic channels to the mAbs. This hybrid affinity agent and the microchip platform may be widely useful for various bio-particle separations in different biological matrices. Further, the regeneration capability of the microchip improves data consistency between multiple uses and minimizes plastic waste while promoting environmental sustainability. STATEMENT OF SIGNIFICANCE: A hybrid affinity agent, Apt-mAb, consisting of a universal aptamer (Apt) that binds the conserved Fc region of monoclonal antibodies (mAbs) was developed. The invented nano-biomaterial combines the strengths and overcomes the weakness of both Apts and mAbs, thus changing the paradigm of affinity separation of cell subtypes. When Apt-mAb was used to fabricate microfluidic chips using a "universal screwdriver" approach, the microchip could be easily tuned to bind any cell type, exhibiting great universality. Besides high sensitivity and selectivity, the superior regenerative capacity of the microchips makes them reusable, which provides improved consistency and repeatability in cell profiling and opens a new approach towards in vitro diagnostic point-of-care testing devices with environmental sustainability and cost-effectiveness.
从全血中同时分离出各种循环肿瘤细胞(CTC)亚型,对癌症诊断和预后评估具有重要意义。微流控亲和分离装置因其高通量能力和自动化特性,在CTC分离方面颇具潜力。然而,目前单独使用的亲和试剂,如抗体(mAbs)和适配体(Apts),在高效、一致且通用的细胞分析方面仍存在不足。通过引入一种混合亲和试剂,即适配体 - 抗体(Apt - mAb)偶联物,我们开发了一种通用且可再生的微芯片,该芯片在从血液中分离和分析各种CTC时具有高效性和非侵入性。Apt - mAb偶联物由特异性结合靶细胞受体的单克隆抗体和识别该mAb保守Fc区域的表面结合适配体组成。然后,适配体将微流控通道的表面功能化与mAbs间接连接起来。这种混合亲和试剂和微芯片平台可能在不同生物基质中的各种生物颗粒分离中具有广泛用途。此外,微芯片的再生能力提高了多次使用之间的数据一致性,并最大限度地减少了塑料废物,同时促进了环境可持续性。重要性声明:开发了一种混合亲和试剂Apt - mAb,它由结合单克隆抗体(mAbs)保守Fc区域的通用适配体(Apt)组成。这种发明的纳米生物材料结合了Apts和mAbs的优点并克服了它们的缺点,从而改变了细胞亚型亲和分离的模式。当使用Apt - mAb通过“通用螺丝刀”方法制造微流控芯片时,该微芯片可以轻松调整以结合任何细胞类型,具有很强的通用性。除了高灵敏度和选择性外,微芯片卓越的再生能力使其可重复使用,这在细胞分析中提供了更高的一致性和可重复性,并为具有环境可持续性和成本效益的体外诊断即时检测设备开辟了新途径。